ABVC BioPharma announces approved plan for pilot Good Manufacturing Practice (GMP) facility to produce Vitargus
The plan is intended to upgrade Vitagrus’ manufacturing process so that it can ultimately handle the global market supply.
Oxurion receives upfront payment of approximately $400,000, contributing to Oxurion’s investment in THR-149
THR-149 is being evaluated in a Phase 2 clinical trial as a potential treatment for diabetic macular edema, which is expected to readout topline results by the end of this year.
Belite Bio concluded enrollment in Pivotal Global Phase 3 DRAGON Trial
Belite Bio has completed patient enrollment for a trial evaluating Tinlarebant, which is the first ever treatment for Stargardt Disease.
Clearside Biomedical starts enrollment of participants in its ODYSSEY Phase 2b clinical trial of CLS-AX
Clearside Biomedical developing a long-acting therapy for the treatment of retinal diseases, including wet AMD.
New study finds estimated 9.6 million people in the US have DR and 1.84 million people have VTDR
A new study titled, “Prevalence of Diabetic Retinopathy in the US in 2021,” finds that almost 10 million people in the United States with diabetes have diabetic retinopathy.
2 Clarke Drive Cranbury, NJ 08512